Skip to main content
MedPathMedPath Home
Clinical Trials/JPRN-UMIN000018665
JPRN-UMIN000018665
Completed
未知

Special Drug Use-results Surveillance for long term administration of XEPLION (Paliperidone Palmitate 1 month formulation), 25mg/ 50mg/ 75mg/ 100mg/ 150mg syringe - Special Drug Use-results Surveillance for long term administration of XEPLION (Paliperidone Palmitate 1 month formulation), 25mg/ 50mg/ 75mg/ 100mg/ 150mg syringe

Janssen Pharmaceutical K.K.0 sites1,050 target enrollmentAugust 13, 2015
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsSchizophrenia

Overview

Phase
未知
Intervention
Not specified
Conditions
Schizophrenia
Sponsor
Janssen Pharmaceutical K.K.
Enrollment
1050
Status
Completed
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
August 13, 2015
End Date
TBD
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
Special Drug Use-results Surveillance for long term administration in adult (18 years and older) of CONCERTA, 18mg/ 27mg/ 36mg TabletsAttention deficit hyperactivity disorder (ADHD)
JPRN-UMIN000015900Janssen Pharmaceutical K.K500
Recruiting
Not Applicable
Special Drug Use Results Surveillance for the use of Odefsey in pregnant womeHIV/AIDS
JPRN-UMIN000034028Janssen Pharmaceutical K.K.3
Completed
Not Applicable
Special drug use results surveillance for the use of SIMPONI in ulcerative colitisulcerative colitis
JPRN-UMIN000027542Janssen Pharmaceutical K.K.300
Recruiting
Not Applicable
Special drug use-results surveillance <Patients with cold agglutinin disease>Cold agglutinin disease
JPRN-UMIN000049607sanofi K.K.100
Recruiting
Not Applicable
Protocol Number; CBAF312A1401
JPRN-jRCT2031200377Sugimoto Toshiya330